Alpha emitter are radioactive elements that decay and emit alpha particles. They are used for targeted alpha therapy which is an emerging type of cancer treatment approach and offers low toxicity when aimed at cancer cells alone. As compared to traditional chemotherapy and radiotherapy, targeted alpha therapy has more selective effects and damages cancer cells more effectively while sparing surrounding healthy tissues.
Market key trends:
One of the major trends fueling the market growth is rising research and development activities for targeted alpha therapies. Many key players are engaged in developing targeted alpha therapies and bringing innovative products into the market. For instance, Actinium Pharmaceuticals is developing Actimab-A which is an alpha emitting monoclonal antibody for acute myeloid leukemia. Another key trend is increasing adoption of targeted alpha therapies due to their benefits over traditional cancer therapies. Targeted alpha therapies offer low side effects, more effective treatment outcomes and can be used for various cancer types. This is increasing their adoption rate globally and driving the alpha emitter market growth.
The global Alpha Emitter Market Share is estimated to be valued at US$ 1,331.0 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Threat of new entrants: Low capital requirement for manufacturing but high costs for R&D and clinical trials pose barriers.
Bargaining power of buyers: Customers have low bargaining power due to limited product availability and specialized production process.
Bargaining power of suppliers: Suppliers have moderate power due to supplier concentration and need for stable isotope supply.
Threat of new substitutes: Substitutes have potential but alpha emitters provide advantages of targeted therapy with minimal systemic side effects.
Competitive rivalry: Intense due to increasing adoption, technological advancements and rising investment in product pipeline.
Strengths: Targeted radiation therapy with minimal side effects. Wide applications in cancer treatment.
Weaknesses: High production costs. Regulatory challenges and risks associated with radioactivity.
Opportunities: Rising cancer prevalence rates. Increasing healthcare expenditure and funding for clinical trials.
Threats: Stringent regulatory approvals. Reimbursement issues. Dependence on isotope suppliers.
The global alpha emitter market is expected to witness high growth at a CAGR of 10.% over the forecast period due to increasing prevalence of cancer worldwide.
North America dominates the alpha emitter market currently and is expected to maintain its leading position over the forecast period. This is attributed to well-established healthcare system, rising healthcare spending, and presence of major market players in the region.
Key players operating in the alpha emitter market are Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation. The market is fragmented in nature with presence of global as well as regional market players.